stockrow
Friday 6 November 2026
Export TGTX’s income statement to Excel — free account
TG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
59.60
1.62
+2.79%
Follow TGTX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
9.71 | 177.06 | 213.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 3 | 5 | 2 | 3 | 4 | 2 | 2 | 4 | 3 |
P/S ratio |
6.98 | 13.29 | 10.35 | 562.55 | 375.58 | 39,471.54 | 6,453.26 | 2,035.62 | 3,573.11 | 1,435.74 |
Altman Z-Score |
6.29 | 5.48 | 3.89 | (6.92) | 3.54 | 31.24 | (4.24) | (12.03) | 1.73 | (2.82) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.04 | (2.08) | (8.68) | (28.94) | (11.18) | 2.58 | (18.06) | (31.04) | (13.35) | (17.69) |
Beneish M-Score |
0.80 | (0.89) | — | — | — | — | — | (5.14) | (3.58) | (5.34) |
P/Operating CF |
218.82 | (170.59) | (183.11) | (65.63) | (28.91) | (115.32) | (32.27) | (9.18) | (24.85) | (12.82) |
P/B ratio |
6.64 | 19.67 | 15.07 | 26.74 | 10.59 | 11.55 | 25.40 | 12.87 | 8.11 | 6.08 |
Price to Tangible BV |
6.65 | 19.74 | 15.15 | 27.11 | 10.63 | 11.57 | 25.94 | 13.32 | 8.20 | 6.22 |
EV/Sales |
7.15 | 13.10 | 9.85 | 530.39 | 338.65 | 35,702.31 | 5,731.82 | 1,583.09 | 3,016.52 | 1,141.20 |
EV/EBITDA |
36.42 | 115.76 | 108.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(177.89) | (106.34) | (73.30) | (8.38) | (7.66) | (25.30) | (6.56) | (1.87) | (4.89) | (2.82) |
EV/FCF |
(176.37) | (106.20) | (73.26) | (8.38) | (7.65) | (25.26) | (6.55) | (1.87) | (4.89) | (2.80) |
Quick Ratio |
2.91 | 4.85 | 5.00 | 3.04 | 4.84 | 6.91 | 1.66 | 1.78 | 3.03 | 2.66 |
Current Ratio |
4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 |
Net Debt/EBITDA |
0.86 | (1.79) | (5.54) | 0.42 | 0.72 | 2.10 | 0.65 | 0.39 | 0.71 | 0.57 |
Debt/Assets |
23.10% | 42.31% | 30.38% | 36.75% | 17.85% | 5.19% | 18.88% | 0.08% | 0.13% | 0.13% |
Debt/Equity |
0.38 | 1.10 | 0.62 | 1.21 | 0.29 | 0.06 | 0.80 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.75 | 0.73 | 0.89 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(0.06) | (1.73) | (2.48) | 0.79 | 0.85 | 0.77 | 0.77 | 0.74 | 0.79 | 0.79 |
Capex/Depreciation |
0.09 | 0.01 | 0.00 | (0.01) | (0.19) | (0.28) | (0.21) | 2.90 | (0.01) | (0.66) |
Interest Coverage |
4.61 | 1.75 | 1.64 | (21.42) | (61.15) | (43.23) | (31.98) | (198.86) | (140.49) | (244.49) |
| 102.75% | 12.21% | 11.57% | (151.36%) | (92.03%) | (100.14%) | (551.85%) | (381.16%) | (230.36%) | (113.87%) | |
| 54.50% | 5.15% | 4.84% | (78.09%) | (69.26%) | (70.85%) | (140.19%) | (191.70%) | (155.72%) | (93.02%) | |
ROIC |
10.25% | 16.82% | 29.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
93.75% | 4.92% | 4.80% | (193.98%) | (130.78%) | (53.25%) | (266.02%) | (429.11%) | (180.58%) | (228.05%) |
Average Days of Receivables |
181.01 | 143.32 | 79.81 | 0.00 | 75.79 | 0.00 | 0.00 | 228.13 | 259.34 | 201.47 |
Research and Development Expense of Revenue |
26.00% | 28.66% | 32.61% | 4,500.97% | 3,327.54% | 109,142.11% | 101,434.21% | 104,862.50% | 67,455.92% | 45,547.37% |
Selling, General and Administrative Expense of Revenue |
37.65% | 46.90% | 52.51% | 3,428.51% | 1,914.93% | 70,953.95% | 9,886.18% | 9,974.34% | 10,744.08% | 6,505.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
10.49% | 12.93% | 16.23% | 1,603.66% | 916.04% | 52,821.71% | 7,457.24% | 8,477.63% | 10,490.13% | 4,940.79% |
Graham Net Nets |
0.05 | 0.05 | 0.06 | 0.02 | 0.08 | 0.08 | 0.03 | 0.06 | 0.12 | 0.15 |
Graham Number |
17.61 | 2.42 | 1.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
10.30% | 0.56% | 0.47% | (14.21%) | (13.84%) | (4.59%) | (17.84%) | (55.91%) | (21.83%) | (35.73%) |
Free Cash Flow Yield |
(0.58%) | (0.93%) | (1.30%) | (11.25%) | (11.78%) | (3.58%) | (13.55%) | (41.70%) | (17.27%) | (28.38%) |
Revenue per Share |
4.27 | 2.26 | 1.65 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.17) | (0.28) | (0.22) | (1.30) | (2.24) | (1.86) | (1.50) | (1.71) | (1.51) | (1.26) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) |
Free Cash Flow per Share |
(0.17) | (0.28) | (0.22) | (1.30) | (2.24) | (1.86) | (1.50) | (1.71) | (1.51) | (1.26) |
Cash per Share |
0.98 | 2.14 | 1.53 | 1.19 | 2.38 | 5.25 | 1.59 | 0.91 | 1.36 | 0.92 |
Shareholders Equity per Share |
4.49 | 1.53 | 1.13 | 0.43 | 1.79 | 4.50 | 0.44 | 0.32 | 1.08 | 0.73 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.49 | 1.53 | 1.13 | 0.43 | 1.79 | 4.50 | 0.44 | 0.32 | 1.08 | 0.73 |
Free Cash Flow |
(24.99) | (40.56) | (31.41) | (176.18) | (296.03) | (214.86) | (132.94) | (129.01) | (93.76) | (61.93) |
Working Capital |
477.00 | 475.68 | 264.22 | 115.07 | 265.58 | 524.19 | 64.70 | 40.18 | 65.36 | 33.99 |
Capital Expenditures |
(0.21) | (0.04) | — | (0.01) | (0.40) | (0.36) | (0.13) | (0.09) | 0.00 | (0.34) |
Net Current Asset Value |
215.53 | 211.03 | 148.86 | 33.29 | 188.49 | 505.45 | 24.75 | 19.45 | 62.93 | 31.95 |
EV/EBIT |
35.73 | 102.76 | 111.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 2.35 | 0.86 | 0.59 | 0.01 | 2.26 |
Price to Operating Income |
34.88 | 104.32 | 117.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 6.61 | 3.49 | 2.64 | 2.18 | (0.12) | 0.58 | 1.59 |
Cash ROIC |
(2.41%) | (5.22%) | (6.57%) | (60.46%) | (47.77%) | (18.57%) | (63.36%) | (138.72%) | (61.75%) | (76.63%) |
Accounts Receivable Turnover |
2.83 | 3.65 | 8.90 | 0.00 | 9.01 | 0.00 | 0.00 | 1.50 | 1.58 | 1.13 |
Accounts Payable Turnover |
1.21 | 0.80 | 0.35 | 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
Inventory Turnover |
0.85 | 0.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
389.62 | 552.88 | 993.70 | 57,875.23 | 23,699.13 | 36,123.29 | 38,882.85 | 150,881.88 | 114,625.06 | 88,455.72 |
Days of Inventory on Hand |
455.14 | 1,047.58 | 1,028.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
217.41 | 90.14 | 26.24 | — | 0.74 | — | — | 0.10 | 0.10 | 0.13 |
Average Payables |
82.90 | 48.38 | 40.25 | 46.66 | 44.15 | 33.53 | 33.21 | 31.13 | 20.57 | 12.31 |
Average Inventory |
118.02 | 75.14 | — | — | — | — | — | — | — | — |
Average Assets |
820.47 | 453.64 | 261.58 | 286.60 | 502.64 | 394.33 | 123.32 | 90.50 | 76.08 | 84.13 |
Average Common Equity |
435.19 | 191.43 | 109.54 | 147.87 | 378.25 | 278.98 | 31.33 | 45.51 | 51.43 | 68.72 |
Columns are period end dates · fundamentals updated 25 Oct 2026